Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Trebananib leveraging anti‐angiogenic mechanism that is distinct from the classic sorafenib anti‐vascular endothelial growth factor inhibition did not demonstrate improved progression‐free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC). In support of p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Abou‐Alfa, Ghassan K., Blanc, Jean‐Frederic, Miles, Steven, Ganten, Tom, Trojan, Jörg, Cebon, Jonathan, Liem, Andre K., Lipton, Lara, Gupta, Charu, Wu, Benjamin, Bass, Michael, Hollywood, Ellen, Ma, Jennifer, Bradley, Margaret, Litten, Jason, Saltz, Leonard B.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507650/
https://ncbi.nlm.nih.gov/pubmed/28592620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados